Aerobic exercise and metformin attenuate the cognitive impairment in an experimental model of type 2 diabetes mellitus: focus on neuroinflammation and adult hippocampal neurogenesis
Metabolic Brain Disease,
Год журнала:
2025,
Номер
40(1)
Опубликована: Янв. 7, 2025
Язык: Английский
Overview of Metformin and Neurodegeneration: A Comprehensive Review
Pharmaceuticals,
Год журнала:
2025,
Номер
18(4), С. 486 - 486
Опубликована: Март 28, 2025
This
comprehensive
review
examines
the
therapeutic
potential
of
metformin,
a
well-established
diabetes
medication,
in
treating
neurodegenerative
disorders.
Originally
used
as
first-line
treatment
for
type
2
diabetes,
recent
studies
have
begun
investigating
metformin’s
effects
beyond
metabolic
disorders,
particularly
its
neuroprotective
capabilities
against
conditions
like
Parkinson’s
disease,
Alzheimer’s
Huntington’s
and
multiple
sclerosis.
Key
findings
demonstrate
that
operate
through
pathways:
AMPK
activation
enhancing
cellular
energy
metabolism
autophagy;
upregulation
antioxidant
defenses;
suppression
inflammation;
inhibition
protein
aggregation;
improvement
mitochondrial
function.
These
mechanisms
collectively
address
common
pathological
features
neurodegeneration
neuroinflammation,
including
oxidative
stress,
accumulation,
dysfunction.
Clinical
preclinical
evidence
supporting
association
with
improved
cognitive
performance,
reduced
risk
dementia,
modulation
hallmarks
diseases
is
critically
evaluated.
While
metformin
shows
promise
agent,
this
emphasizes
need
further
investigation
to
fully
understand
optimal
applications
diseases.
Язык: Английский
Sappanone A mitigates cognitive impairment and oxidative stress through modulation of alpha7 nicotinic acetylcholine receptor in rats with trimethyltin-induced Alzheimer’s disease-like condition
Pharmacological Research - Modern Chinese Medicine,
Год журнала:
2025,
Номер
unknown, С. 100619 - 100619
Опубликована: Апрель 1, 2025
Язык: Английский